Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors

Vandana G. Abramson, Jeffrey G. Supko, Tarah Ballinger, James M. Cleary, John F. Hilton, Sara M. Tolaney, Nicole G. Chau, Daniel C. Cho, Joseph Pearlberg, Joanne Lager, Geoffrey I. Shapiro, Carlos L. Arteaga

Research output: Contribution to journalArticle

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)3520-3528
Number of pages9
JournalClinical Cancer Research
Issue number14
Publication statusPublished - Jul 15 2017


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this